Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NEMLUVIO vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nemolizumab is a humanized monoclonal antibody that binds to the interleukin-31 receptor alpha (IL-31RA), blocking IL-31 signaling. IL-31 is a cytokine involved in pruritus, inflammation, and barrier dysfunction in atopic dermatitis and other conditions.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Treatment of pruritus associated with atopic dermatitis in adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies.
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
2 mg orally once daily.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
The terminal elimination half-life is approximately 40 hours (range 35-50 hours), supporting once-daily dosing for sustained therapeutic effect.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Nemolizumab is a monoclonal antibody expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Renal excretion of unchanged drug accounts for approximately 30% of the administered dose; fecal elimination via biliary excretion accounts for approximately 60%; the remainder is metabolized and excreted as metabolites.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
99.5% bound to plasma proteins, primarily albumin.
82–88% bound to plasma proteins (primarily albumin).
Volume of distribution is 0.45 L/kg, indicating distribution primarily into extracellular fluid and limited tissue penetration.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Oral bioavailability is 75% under fasting conditions; administration with a high-fat meal reduces bioavailability to approximately 60%.
Oral: 65–80% (median 73%)
Not recommended if e GFR <15 m L/min/1.73 m². No adjustment for e GFR ≥15.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Child-Pugh A: no adjustment; Child-Pugh B or C: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Not established for patients <18 years.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific dose adjustment; use caution due to potential renal impairment.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
None.
None
Hypersensitivity reactions including anaphylaxis have been reported.,Eczema herpeticum (Kaposi's varicelliform eruption) has been observed in clinical trials.,Potential increased risk of serious infections (e.g., parasitic infections) due to IL-31 inhibition.,Prior to initiation, patients should be evaluated for helminth infections and treated if infected.,Monitor for signs and symptoms of hypersensitivity reactions during and after administration.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
History of hypersensitivity to nemolizumab or any excipients in the formulation.,Clinically significant helminth infection (e.g., parasitic worm infection) until treatment and resolution of infection.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
Avoid grapefruit and grapefruit juice as they may increase NEMLUVIO levels. High-fat meals may delay absorption but do not affect overall exposure. Limit caffeine intake as it may exacerbate side effects.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
NEMLUVIO (narlaprevir) is contraindicated in pregnancy due to observed fetal toxicity in animal studies. In rats and rabbits, maternal exposure at 0.2–0.5 times the human exposure (AUC) resulted in increased fetal resorptions, reduced fetal body weight, and skeletal abnormalities including misshapen sternebrae and delayed ossification. No human data are available; however, the drug's mechanism (inhibition of viral protease) and animal findings indicate a high risk of teratogenicity (FDA Pregnancy Category X). First trimester exposure carries the highest risk of major malformations. Second and third trimester exposure may cause fetal growth restriction and potential neurodevelopmental effects.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
No data exist on the presence of narlaprevir in human milk, its effects on the breastfed infant, or its effects on milk production. In lactating rats, narlaprevir was excreted in milk at concentrations similar to maternal plasma (milk-to-plasma ratio approximately 1.0). Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during NEMLUVIO therapy and for 7 days after the last dose.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
NEMLUVIO is contraindicated in pregnancy; therefore, no dose adjustment is recommended. If a pregnant woman inadvertently receives the drug, discontinue immediately; pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may lead to subtherapeutic concentrations, but no dosing guidance can be provided due to the contraindication. Use in pregnant patients is not appropriate under any circumstances.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
NEMLUVIO is a selective norepinephrine reuptake inhibitor indicated for fibromyalgia. Monitor for blood pressure elevation; titrate dose slowly to minimize adverse effects. Discontinue gradually to avoid withdrawal syndrome. Use with caution in patients with cardiovascular disease or recent myocardial infarction.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Take NEMLUVIO exactly as prescribed, usually once daily with or without food.,Avoid driving or operating heavy machinery until you know how this medication affects you, as it may cause dizziness or somnolence.,Do not stop taking NEMLUVIO abruptly, as this may cause withdrawal symptoms such as headache, nausea, or insomnia.,Notify your healthcare provider if you experience rapid heart rate, chest pain, or severe headache.,Limit alcohol intake while on NEMLUVIO as it may increase risk of liver injury or worsen side effects.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NEMLUVIO vs AGRYLIN, answered by our medical review team.
NEMLUVIO is a Antineoplastic Agent that works by Nemolizumab is a humanized monoclonal antibody that binds to the interleukin-31 receptor alpha (IL-31RA), blocking IL-31 signaling. IL-31 is a cytokine involved in pruritus, inflammation, and barrier dysfunction in atopic dermatitis and other conditions.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NEMLUVIO and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NEMLUVIO is: 2 mg orally once daily.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NEMLUVIO and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NEMLUVIO is classified as Category C. NEMLUVIO (narlaprevir) is contraindicated in pregnancy due to observed fetal toxicity in animal studies. In rats and rabbits, maternal exposure at 0.2–0.5 times the human exposure . AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.